Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy Nasdaq
SYDNEY, Australia, June 21, 2019– Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune.
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy Nasdaq
SYDNEY, Australia, June 21, 2019– Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune.